Prescribing Pattern and Utilization of Antihypertensive Drugs and Blood Pressure Control in Adult Patients with Systemic Hypertension in a Rural Tertiary Hospital in Nigeria
American Journal of Internal Medicine
Volume 2, Issue 6, November 2014, Pages: 144-149
Received: Dec. 14, 2014; Accepted: Dec. 17, 2014; Published: Dec. 23, 2014
Views 3102      Downloads 235
Authors
Olusegun Adesola Busari, Department of Internal Medicine, Federal Medical Centre, Ido-Ekiti, Nigeria
Rotimi Oluyonbo, Department of Internal Medicine, Federal Medical Centre, Ido-Ekiti, Nigeria
Abidemi Jude Fasae, Department of Internal Medicine, Federal Medical Centre, Ido-Ekiti, Nigeria
Olusegun Emanuel Gabriel, Department of Family Medicine, Federal Medical Centre, Ido-Ekiti, Nigeria
Lawrence Majekodunmi Ayodele, Department of Mental Health, Federal Medical Centre, Ido-Ekiti, Nigeria
Segun Matthew Agboola, Department of Family Medicine, Federal Medical Centre, Ido-Ekiti, Nigeria
Adekunle OlatayoAdeoti, Department of Internal Medicine, University Teaching Hospital, Ado-Ekiti, Nigeria
Article Tools
Follow on us
Abstract
Background: Hypertension is a major public health concern globally and is associated with high morbidity and mortality in sub-Saharan Africa. Although antihypertensive therapy is effective in lowering blood pressure, a large proportion of patients do not have optimal blood pressure control. Aims: To describe the prescribing pattern and utilization of antihypertensive drugs and assess blood pressure control in a rural reference tertiary hospital in Nigeria. Methods: We conducted a cross-sectional study of 212 adult patients with hypertension attending the cardiology clinic of the Federal Medical Centre, Ido-Ekiti, Nigeria, between February 2012 and July 2012. Anthropometric, clinical and therapeutic data were collected using a pre-tested pro forma. Data analysis was done using SPSS 16.0 software (IBM, Chicago, Il, US). P value < 0.05 (two-sided test) was considered to be statistically significant. Results: We study 212 adults with hypertension, 48.1% of whom were male and the male-to-female ratio was 0.9. The mean age (± SD) of the patients was 61.5±15.1 years. Thirty two (15.1%), 95 (44.8%), 67 (31.6%) and 18 (8.5%) patients were on mono-, dual-, triple- and quadruple therapy respectively. Diuretics (84.9%) and calcium channel blockers (56.6%) were the most frequently used antihypertensive drugs. Blood pressure was controlled in only 45.3% of patients. Dual- and triple-therapy produced more patients with controlled blood pressure (dual-therapy, p=0.30; triple-therapy, p=0.11). Conclusions: Our study showed that diuretics were the most frequently prescribed class of antihypertensive drugs in our rural tertiary hospital as in many studies from urban centres in Nigeria and sub-Saharan Africa. Consistent with the global trend, the rate of controlled blood pressure among hypertensive patients was low, with combination therapy achieving control in more patients.
Keywords
Hypertension, Antihypertensive Drugs, Prescribing Pattern, Blood Pressure Control, Sub-Saharan Africa, Adherence
To cite this article
Olusegun Adesola Busari, Rotimi Oluyonbo, Abidemi Jude Fasae, Olusegun Emanuel Gabriel, Lawrence Majekodunmi Ayodele, Segun Matthew Agboola, Adekunle OlatayoAdeoti, Prescribing Pattern and Utilization of Antihypertensive Drugs and Blood Pressure Control in Adult Patients with Systemic Hypertension in a Rural Tertiary Hospital in Nigeria, American Journal of Internal Medicine. Vol. 2, No. 6, 2014, pp. 144-149. doi: 10.11648/j.ajim.20140206.18
References
[1]
Gaziano TA. Economic burden and the cost-effectiveness of treatment of cardiovascular diseases in Africa. Heart. 2008; 94 (2):140-4.
[2]
Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens. 2004; 22(1):11–9.
[3]
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005; 365(9455):217–23.
[4]
Le Heuzey JY, Guize L. Cardiac prognosis in hypertensive patients. Am J Med. 1988; 84: 65–8.
[5]
Akinkugbe OO. The epidemiology of hypertension in Africa. In: Akinkugbe, ed. Cardiovascular diseases in Africa. Ciba-Geigy, 1976: 91-100.
[6]
Adedoyin RA, Mbada CE, Balogun MO, Martins T, Adebayo RA, Akintomide A., et al. Prevalence and pattern of hypertension in a semi-urban community in Nigeria.Eur J CardiovascPrevRehabil. 2008, 15(6):683-7.
[7]
Ofuya Z.The incidence of hypertension among a select population of adults in the Niger Delta region of Nigeria. Southeast Asian J Trop Med Public Health2007; 38(5): 947-9
[8]
Oladipo B, Akinkungbe. Current epidemiology of hypertension in Nigeria. Archives of Ibadan Medicine 2001; 1(1): 4- 8.
[9]
Oladapo OO, Falase AO, Salako L, Sodiq O, Shoyinka K, Adedapo K. A prevalence of cardiometabolic risk factors among a rural Yoruba south-western Nigerian population: a population-based survey. Cardiovasc J Afr. 2010; 21(1):26-31.
[10]
Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists and other blood-pressure lowering drugs. Results of prospectively designed overviews of randomized trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet 2000; 356; 1955-64.
[11]
Pasty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckberk SR et al. Health outcomes associated with antihypertensive therapies used as first line agents. A systematic review and meta-analysis. JAMA 1997; 277: 739-45
[12]
Lemogoum D, Seedat YK, Mabadeje AFB, Mendis S, Bovet P, Onwubere B et al. Recommendation for prevention, diagnosis and management of hypertension and cardiovascular risk factors in sub Saharan Africa. J Hypertension 2003; 21: 1993-2000,
[13]
Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grim RH, et al. Success and predictors of blood pressure control in diverse North American settings. The Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J ClinHypertens2002; 4:339-40.
[14]
Olanrewaju TO, Aderibigbe A, Busari OA, Sanya EO. Antihypertensive drug utilization and conformity to guidelines in a sub- Saharan African hypertensive population. International Journal of ClinicalPharmacology and Therapeutics 2010; 48(1): 68-75.
[15]
Busari OA, Olarewaju TO, Desalu OO, Opadijo GO, Jimoh AK, Agboola SM, Busari OE, et al. Impact of knowledge, attitudes and practices on hypertension on compliance with antihypertensive drugs in a resource-poor setting. TAF Preventive Medicine Bulletin 2010; 9(2)87-92.
[16]
Psaty BM, Manolio TA, Smith NL, Heckbert SR, Gotdiener JS, Burke GL, et al. Time trends in high blood pressure control and the use of antihypertensive medication in older adults. The Cardiovascular Health Study. Archive of Internal Medicine2002; 162: 2325-32.
[17]
Marques-Vidal P, Tuomilehto J. Hypertension awareness, treatment and control in the community. Is the ‘rule of halves’ still valid? J Human Hypertens1997; 11: 213-20.
[18]
Primastesta P, Brookes M, Poulter NR. Improved hypertension management and control. Results from the Health Survey for England 1998. Hypertension 2001; 3: 827-832.
[19]
Okano G J, Rascati K L, Wilson J P, Remund D D, Grabenstein J B, Brixner D I. Patterns of antihypertensive use among patients in the US Department of Defense database initially prescribed an angiotensin converting enzyme inhibitor or calcium channel blocker. Clin Therapeutics1997;19:1433-35.
[20]
Monae M, Bohn R L, Gurwitz J H, Glynn R J, Levin R, Avorn J. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in elderly. Am J Hypertens 1997; 10: 697-704.
[21]
EkwunifeOI,Ubaka CM. Drug utilization of antihypertensive therapy among patients with compelling indications in two hospitals in south-eastern Nigeria. J Pharm Pharmacol Res 2011; 2(1): 25-28
[22]
Etuk, K, Isezuo SA, Chika A, Achuje A, Ali M. Prescription pattern of antihypertensive drugs in a tertiary health institution in Nigeria. Ann Afr Med 2008; 7: 128-132
[23]
Yusuff KB,Balogun OB. Physicians’ prescribing of antihypertensive combinations in a tertiary care setting in southwest Nigeria. J Pharm PhamaceutSci 2005; 8: 235-242
[24]
Alebiousu CO. Antidiabetics/ antihypertensives prescription profile in OSUTH, Sagamu and environment. Niger J ClinPract 2004; 7(1): 15-20.
[25]
Amira CO, Okubadejo NU. Antihypertensive pharmacotherapy in a developing economy: pattern, acquisition costs and conformity to international guidelines in a tertiary-care setting. J Human Hypertens 2006; 20: 894-897.
[26]
Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al.The Task Force for the Management of Arterial Hypertension of theEuropean Society of Hypertension and of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension. Eur Heart J 2007; 28: 1462–1536.
[27]
Guidelines Committee 2003. European Society of Hypertension-European Society of Cardiology guidelines for the management ofarterial hypertension. J Hypertens2003;21:1011–1053.
[28]
Potchoo Y, Goe-Akue E, Damorou F, Massoka B, Redah D, Guissou IP. Effect of Antihypertensive Drug Therapy on the Blood Pressure Control among Hypertensive Patients Attending Campus’ Teaching Hospital of Lome, Togo, West Africa. Pharmacology & Pharmacy, 2012; 3; 214-223
[29]
Tamuno I, Babashani M. Blood pressure control among hypertensive patients in a tertiary health care facility in Northern Nigeria. Research Journal of Medical Sciences 2012; 6(1): 26-32
[30]
Katibi IA, Olarinoye JK. Antihypertensive therapy among hypertensive patients as seen in the middle belt of Nigeria. Ann Afr Med 2004; 3: 177-180
[31]
Salako BM, Ayodele OE, Kadiri S, Arije A. Assessment of blood pressure in a black African population. Cardiol Trop 2002; 9: 3-6
[32]
National Expert Committee on Noncommunicable Diseases. Noncommunicable disease in Nigeria-final report of a national survey, Lagos, Nigeria: Federal Ministry of Health and Social Services; 1997.
[33]
Odili VU, Oghagbon EK, Ugua NA, Ochei UM, Aghomo OE. Adherence to international guidelines in the management of hypertension in a tertiary hospital in Nigeria. Trop J Pharmaceut Res 2008; 7: 945-952.
[34]
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 Report, JAMA 2003; 289; 2560-2571
[35]
World Health Organization, International Society of Hypertension Writing Group 2003. World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1989-1992
[36]
O’Riordan M. New European Hypertension Guidelines Released: Goal Is Less Than 140mmHg for All. Medscape (serial online). Available at http://www.medscape.com/viewarticle/806367. Accessed July 30, 2013
[37]
Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension.. 23rd European Meeting on Hypertension and Cardiovascular Protection. Available at http://www.esh2013.org/wordpress/wp-content/uploads/2013/06/ESC-ESH-Guidelines-2013.pdf. Accessed July 30, 2013
[38]
Institute for Clinical Systems Improvement (ICSI). Hypertension diagnosis and treatment. Bloomington, Minn: Institute for Clinical Systems Improvement (ICSI); 2010.
[39]
Whelton PK, Appel LJ, Sacco RL, Anderson CA, Antman EM, Campbell N, et al. Sodium, blood pressure and cardiovascular disease: further evidence supporting the American Heart Association Sodium Reduction Recommendations. Circulation 2012; 126(24): 2880-2889
[40]
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Programme (SHEP). SHEP Cooperative Research Group. JAMA 1991; 265(24): 3255-64
[41]
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blockers versus diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997
[42]
Kostis JB, Cabrera J, Cheng JQ, Cosgrove NM, Deng Y, Pressel SL, et al. Associatino between chlorthalidone treatment of systolic hypertension and long term survival. JAMA 2011; 306(23): 2588-2593
[43]
Seedat YK. Hypertension in developing nations in sub Saharan Africa. J Human Hypertens 2000: 14: 739-747
[44]
Mokhobo KP. Arterial hypertension in rural societies. East Afr Med J 1976; 53: 440-444
[45]
Oviasu VO. Arterial blood pressures and hypertension in a rural Nigerian communities. Afr J Med Sci 1978; 7: 137-143
[46]
Mbanya JC, Minkoulou EM, Salah JN, Balkau B. The prevalence of hypertension in rural and urban Cameroun. Int J Epidemiol 1998: 27: 181-185
[47]
Benz JR, Black HR, Graff A, Reed A, Fitzsimmons S, Shi Y. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy.J Hum Hypertens 1998;12(12):861-6
[48]
Pool JL, Glazer R, Weinberger M, Alvarado R, Huang J, Graff A. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults.ClinTher. 2007; 29(1):61-73
[49]
Glorioso N, Thomas M, Troffa C, Argiolas G, Patel S, Baek I, Zhang J. Antihypertensive efficacy and tolerability of aliskiren/amlodipine single- pill combinations in patients with an inadequate response to aliskirenmonotherapy. CurrVascPharmacol. 2012;10(6):748-55
[50]
Pfeiffer D, Rennie N, Papst CC, Zhang J.Efficacy and tolerability of aliskiren/amlodipine single-pill combinations in patients who did not respond fully to amlodipine mono-therapy. CurrVascPharmacol. 2012;10(6):773-80
[51]
Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008; 336: 1114. Doi:http://dx.doi.org/10.1136/bmj.39553.670231.25. Accessed 1 November 2013.
[52]
Hyre AD, Krouset-Wood MA, Muntner P, Kawasaki L, DeSalvo KB. Prevalence and predictors of poor antihypertensive medication adherence in an urban health clinic setting. J ClinHypertens 2007; 9: 179-186.
[53]
Fitz-Simon N, Benett K, Feily J. A review of studies of adherence with antihypertensive drugs using prescription databases. TherClin Risk Manag 2005; 1(2): 93-106
[54]
Waeber B, Burnier M, Brunner HR. Compliance with antihypertensive treatment. ClinExpHypertens 1999; 21: 973-85
[55]
Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens 2006; 19: 1190-6
[56]
World Health Organization. Adherence to long-term therapies. Geneva: WHO; 2003, pg 79
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186